RNA vaccine

Cell and Gene Therapy Companies Leverage GenScript's cGMP sgRNA Capability to Accelerate Speed to Market

Retrieved on: 
Thursday, December 15, 2022

PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript's 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials.

Key Points: 
  • GenScript's 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials.
  • BRL-201 was developed using Quikin CART, BRL's non-viral site-specific integration platform, which can produce CAR-T cell products using one-step, non-viral preparation.
  • Earlier this year, another China-based cell therapy company also utilized GenScript's cGMP sgRNA capability and received IND clearance for an autologous hematopoietic stem-cell gene-editing therapy.
  • GenScript is committed to advancing non-viral gene and cell therapy development by providing cGMP materials that meet our clients' demanding timelines."

GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study

Retrieved on: 
Thursday, September 22, 2022

PISCATAWAY, N.J., Sept. 22, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods.

Key Points: 
  • A new study, published in Nature Biotechnology , details methods for achieving highly efficient non-viral knock-in using GenScript's GenExactsingle-strand DNA (ssDNA) modified with Cas9-target sequences (CTS).
  • However, difficulties manufacturing large amounts of clinical-grade viral vectors have delayed getting cell therapies to patients.
  • "We are very proud to have collaborated on this groundbreaking scale-up work by the talented team at Gladstone and UCSF.
  • ", said first author Brian Shy, MD, PhD, a former clinical fellow in the lab of Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology.

GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process

Retrieved on: 
Tuesday, September 20, 2022

PISCATAWAY, N.J. and DUBLIN, Sept. 20, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider and Avectas, a cell engineering technology leader, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies share a goal of providing their customers with potent, new methods for developing cell therapies that offer an improved safety profile over viral and non-viral vector techniques.

Key Points: 
  • By combining Avectas' cell engineering technology and know-how with GenScript's expertise in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for cell therapy manufacturing and to improve editing efficiency and cell viability over traditional delivery methods.
  • CRISPR-based non-viral gene editing methods have gained popularity among research teams following concerns about the FDA's recent draft guidance on the use of viruses for gene and cell therapy.
  • GenScript is collaborating with both academic and industry partners in the development of CRISPR non-viral gene editingto enable next-generation gene- and cell-therapy R&D projects.
  • Avectas is a cell engineering technology business that has developed a unique delivery platform to enable theex vivomanufacture of gene-modified cell therapy products that retain highin vivofunctionality.

Synthego Expands Capabilities of Halo Platform with Next-Generation Manufacturing Facility

Retrieved on: 
Tuesday, July 26, 2022

Synthego, the genome engineering company, announced today that the company has broken ground on a 20,000-square-foot manufacturing facility designed to accelerate translational and clinical research development timelines for cell and gene therapies to as little as a year.

Key Points: 
  • Synthego, the genome engineering company, announced today that the company has broken ground on a 20,000-square-foot manufacturing facility designed to accelerate translational and clinical research development timelines for cell and gene therapies to as little as a year.
  • The next-generation good manufacturing practices (GMP) factory, an expansion of the Halo Platform, will enable Synthego to significantly expand production of its precision gene editing tools which support a broad panel of nucleases, and meet the needs of biopharma customers who are advancing the research and development of CRISPR-mediated gene therapies.
  • The new facility is expected to become operational in late 2022, with a significant amount of capacity pre-allocated and prioritized for development partners.
  • Synthego was founded to revolutionize genome engineering technology, helping translate genomics into the clinic and ultimately making engineered biological therapies accessible to all patients.

CVC maintains strong US patent portfolio covering CRISPR/Cas9 despite PTAB ruling, reports ERS Genomics

Retrieved on: 
Tuesday, March 1, 2022

CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.

Key Points: 
  • CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.
  • These patents cover a variety of compositions and methods for CRISPR/Cas9 gene editing, including dual-guide and single-guide formats.
  • In addition to its substantial portfolio of granted CRISPR/Cas9 patents in the US, CVC maintains fundamental CRISPR/Cas9 patents in over 80 countries including the EU, China, Japan and elsewhere.
  • Eric Rhodes, CEO of ERS Genomics said; "We remain convinced that the compositions, methods and techniques in the CVC portfolio of patents are the essential intellectual property for the practice of CRISPR/Cas9 gene editing."

CVC maintains strong US patent portfolio covering CRISPR/Cas9 despite PTAB ruling, reports ERS Genomics

Retrieved on: 
Tuesday, March 1, 2022

CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.

Key Points: 
  • CVC retains its patent rights in over 40 issued US patents that were never involved in this interference.
  • These patents cover a variety of compositions and methods for CRISPR/Cas9 gene editing, including dual-guide and single-guide formats.
  • In addition to its substantial portfolio of granted CRISPR/Cas9 patents in the US, CVC maintains fundamental CRISPR/Cas9 patents in over 80 countries including the EU, China, Japan and elsewhere.
  • Eric Rhodes, CEO of ERS Genomics said; "We remain convinced that the compositions, methods and techniques in the CVC portfolio of patents are the essential intellectual property for the practice of CRISPR/Cas9 gene editing."

Stories of the Pandemic, mRNA Vaccines, Atoms, Planet Earth, and the Big Bang Come Alive for Children in Two 2021 Award-Winning Illustrated Children's STEM Books

Retrieved on: 
Wednesday, August 4, 2021

They learn in simple terms about the genetic code, DNA, cell biology, viruses, bacteria, vaccines, RNA, and messenger RNA (mRNA).

Key Points: 
  • They learn in simple terms about the genetic code, DNA, cell biology, viruses, bacteria, vaccines, RNA, and messenger RNA (mRNA).
  • Our COVID-19-Coronavirus LEARNING PAGEincludes eight illustrated short stories, video links, lesson plans, and questions.
  • LEARNING PAGES for Atoms, Planet Earth, and The Universe are also available on the Educators tab of TheStardustMystery.com web site.
  • "There are so many wonderful and exciting stories in science to tell," said Dr. Peter Solomon, CEO of TheBeamer LLC.

Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic

Retrieved on: 
Monday, August 2, 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-6231, the Companys mRNA-encoded IL-2 modified for the expansion of regulatory T cells.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-6231, the Companys mRNA-encoded IL-2 modified for the expansion of regulatory T cells.
  • This is our first mRNA autoimmune candidate, and the first to be subcutaneously administered.
  • Today marks another important step in our mission to deliver on the promise of mRNA to help patients across diseases.
  • Moderna now has active clinic programs in five different therapeutic areas: infectious disease, oncology, cardiovascular, rare disease and autoimmune disease.

Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa

Retrieved on: 
Monday, July 26, 2021

The companys project is part of a programme by the kENUP Foundation to accelerating the eradication of Malaria.

Key Points: 
  • The companys project is part of a programme by the kENUP Foundation to accelerating the eradication of Malaria.
  • BioNTech aims to develop a safe and highly effective mRNA vaccine with durable protective immunity for prevention of malaria and disease associated mortality.
  • BioNTech and Pfizer pledged to deliver two billion doses of their COVID-19 vaccine to middle- and low-income countries over the next 18 months.
  • BioNTechs work on Malaria and end-to-end vaccine manufacturing in Africa will initially be fully funded by the company from internal resources.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Retrieved on: 
Thursday, July 22, 2021

SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D). 

Key Points: 
  • Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
  • As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
  • Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants.
  • mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics.